Rankin Aubrey 4
4 · Revance Therapeutics, Inc. · Filed Feb 4, 2021
Insider Transaction Report
Form 4
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
- Award
Common Stock
2021-02-02+11,905→ 79,776 total - Award
Employee Stock Option (Right to Buy)
2021-02-02+21,540→ 21,540 totalExercise: $28.01Exp: 2031-02-01→ Common Stock (21,540 underlying)
Holdings
- 174,302(indirect: By Trust)
Common Stock
- 444,446(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2021, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- [F2]These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
- [F3]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
- [F4]The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2021, subject to Mr. Rankin's Continuous Service (as defined in the Plan) on each vesting date.